Belgium· BE-AMP-SAM521697-00
Lartruvo 10 mg/ml
A olaratumab product containing olaratumab, registered in Belgium by Eli Lilly Nederland. The same ATC class is registered in 3 of our 19 countries.
Checked against FAMHP / AFMPS (Belgium) on
Informational only — not a medical device.
Where it is registered
Olaratumab is registered in 3 of 19 countries.
Countries holding a registration under ATC L01FX10 (olaratumab), each read from that country’s own register.
- This record: Belgium, from FAMHP / AFMPS (Belgium)
- 2 of them publish a price we can compare per daily dose
Olaratumab · ATC L01FX10
3 / 19 countries
- Belgiumprice
- Finlandprice
- United Kingdom
The record
At a glance
FAMHP / AFMPS (Belgium)- Active substance
- Olaratumab
- Manufacturer
- Eli Lilly Nederland
- Country
- Belgium (BE)
- ATC code
- L01FX10
- ATC class
- Olaratumab
- Defined daily dose
- 0.1 g, P
- Reimbursed
- Not published by this register
- Source register
- FAMHP / AFMPS (Belgium)
- Last checked
- September 26, 2026
Packs & prices · 2
- be_apb3661717
- be_apb7721855
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
56 interactions on record for olaratumab.
Graded by severity as the source publishes them — 28 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Olaratumab · interactions on record
56 records
- 28 severe
- 28 moderate
Most severe, free to view
- CladribineL01BB04severe
- Talimogene laherparepvecL01XL02severe
- Talimogen laherparepvecL01XX51severe
- LeflunomidL04AA13severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Olaratumab in 3 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FAMHP / AFMPS (Belgium). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/9e660787-ca7f-4925-bf32-2c9ab4da6494 GET /v1/drugs/9e660787-ca7f-4925-bf32-2c9ab4da6494?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Concentrate for solution for infusion",
"source": "afmps",
"status": "REVOKED",
"name_en": "Lartruvo 10 mg/ml",
"name_fr": "Lartruvo 10 mg/ml",
"name_nl": "Lartruvo 10 mg/ml",
"amp_code": "SAM521697-00",
"strengths": [
"10.0000",
"10.0000"
],
"pack_count": 2,
"substances": [
"Olaratumab"
],
"medicine_type": "ALLOPATHIC",
"atc_description": "Olaratumab",
"authorisation_numbers": [
"EU/1/16/1143/003",
"EU/1/16/1143/002"
]
}See everything about olaratumab.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.